Frankfurt Rhine-Main Metropolitan Area
Currently CEO of Symeres. R&D executive with 25 year experience and strong track record in Pharma and Biotech R&D as well as CRO/CDMO industry. Successful in turnaround and sustained growth situations. Passionate people manager with can-do attitude as well as strategic and entrepreneurial mindset. Co-founder, board member and former CEO of Lario Therapeutics, Limited. Lario is a precision medicine based UK biotech focussed on the development of novel therapeutics for severe pediatric epilepsies (DEE‘s) and other neurological disorders including Parkinson‘s. Former President R&D at Aptuit and key member of the team responsible for growth and successful sale of Aptuit to Evotec AG (8'17) producing a $300M value creation for the private equity owner. Strong business acumen including full P&L oversight, successful M&A, biotech VC fundraising and licensing deals. Experienced advisor to the biotech / pharma industry as well as private equity firms. Member of the Inflexion Health Care Advisory Board. Global executive MBA from IMD Lausanne, Switzerland (EMBA Class of June 2018).
Leading UK-based integrated Contract, Development and Manufacturing Organisation (CDMO). Partner of choice for oral, nasal and pulmonary dosage forms.
Edinburgh-based Lario Therapeutics Limited was founded in November 2021 to develop first-in-class precision medicines as disease-modifying treatments for severe neurological disorders, including epileptic conditions and Parkinson’s disease. The Company’s rapidly advancing pipeline is based on genetically validated targets and promises broad therapeutic potential, with a chance to slow the progression of these devastating early childhood syndromes and adult neurological disorders. Lario Tx’s focus is on the development of therapies for severe pediatric epilepsies for which there is currently a very high unmet medical need.
Epidarex Exeed Ltd. (Exeed) is the recently formed therapeutic discovery engine of Epidarex Capital, a leading transatlantic venture fund. Focussed on advancing early stage, innovative life science assets, Exeed will pair world-class science with leading drug discovery, project management and CRO partners under the leadership of a highly experienced and skilled management team, with seed funds provided by Epidarex Capital. www.epidarex-exeed.com